Reading QTRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QTRX free→Reading QTRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QTRX free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality cannot be assessed as the company was unprofitable over the past year, and risk is high. The sector backdrop is a headwind, and compared with sector peers, QTRX is typical. Peer multiples imply a price about 82% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.10. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.10 QTRX trades at 1× p/s, below its 3× p/s peer median. Our $17 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 81% below a flat-multiple fair value, below our forecast of about 11%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.42 → $-0.40 (+3.2% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 0% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$255.
How much price usually moves either way.
On a bad day, this stock has moved -$791.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,886.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Improving operating income shows the company is managing costs better. It's key for long-term health.
Confirms:Operating income improves year over year by more than 5%.
Disproves:Operating income is lower than last year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for QTRX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Chief Financial Officer and Treasurer — Jason Faessler: The company has hired a new CFO and Treasurer from an external candidate.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
QTRX Quanterix Corp. | Typical Show detailsSector percentile: 46 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on improving gross margin through operational efficiencies and cost management.
Drive revenue growth through strategic initiatives and market expansion.
Strive to improve operating income through cost control and efficiency measures.
Why it matters: Improving gross margin is a top priority for the company. It signals better cost management.
Confirms:Gross margin improves year over year by more than 2%.
Disproves:Gross margin declines year over year or stays flat.
Why it matters: A new CFO can change financial strategy. This could affect earnings and investor confidence.
Confirms one read:Q2 earnings show better financial results after the CFO change.
Confirms the other:Q2 earnings show no improvement or worsen after the CFO transition.
Why it matters: Enhancing revenue growth is crucial. It shows the company's ability to expand its market.
Confirms one read:Revenue growth exceeds 10% year over year.
Confirms the other:Revenue growth is below 5% year over year.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 14, 2026, Anthony Catalano was appointed as the Chief Operating Officer of Quanterix Corporation (the “Company”). Mr. Catalano mostly recently was employed by Flagship Pioneering, Inc. as Senior Vice of President Real Estate and Asset Management from September 2025 to May 2026. Prior to Flagship Pioneering, from July 2025 to August 2025, he…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Vandana Sriram will be leaving Quanterix Corporation (the “Company”) and will no longer serve as the Chief Financial Officer and Treasurer of the Company effective June 15, 2026. Ms. Sriram will receive severance benefits in accordance with the terms of her employment agreement with the Company, as amended, consisting of the continued payment of he…
of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. On March 2, 2026, Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 (the “Earnings Release”). A copy of the Earnings Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…